Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer Female|Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions: DRUG: Palbociclib|DRUG: Endocrine therapy
Sponsor: Kyoto Breast Cancer Research Network
Collaborators: Pfizer